Medical University of Warsaw

www.wum.edu.pl
Warsaw, Poland

The Medical University of Warsaw was founded in January 1950, building on the University of Warsaw's former Faculty of Medicine, which had been established in the early nineteenth century. The Medical University of Warsaw is the largest medical school in Poland, and one of the most prestigious. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

News Article | May 18, 2017
Site: globenewswire.com

SAN DIEGO, May 17, 2017 (GLOBE NEWSWIRE) -- Today at the Paris Course on Revascularization (“EuroPCR”), REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) sponsored a symposium entitled, Fantom: performance gains and clinical data for a next generation BRS, which highlighted the recently announced clinical data from the FANTOM II trial. Information regarding the Company’s newly initiated clinical trials and plans for expansion was also presented. Dr. Alexandre Abizaid, Director of Invasive Cardiology at Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, provided a thorough review of the 12-month clinical results from the FANTOM II trial, which were released by the Company yesterday. The results, which included a very low 4.2% rate of Major Adverse Cardiac Events (“MACE”), demonstrate a strong safety profile for Fantom through a sustained timeframe. Dr. Neils Holm from the Skejby-Aarhus University Hospital in Aarhus, Denmark expanded on the nine-month Optical Coherence Tomography (“OCT”) results that were also released by the Company yesterday. The OCT imaging results in a subset of patients treated with Fantom demonstrated vessel patency (maintenance of a wide open artery) and sustained healing with greater than 99% strut coverage at nine months. Dr. Lukasz Koltowski from the Medical University of Warsaw in Poland and Dr. Matthias Lutz from Universitätsklinikum Schleswig-Holstein in Kiel Germany presented a selection of patient case examples from REVA’s recently initiated clinical trials. The FANTOM II Cohort C trial is evaluating the use of Fantom in longer lesions and in multiple vessels. FANTOM AMI is evaluating Fantom in patients that present with an acute myocardial infarction (“AMI”). Each of these trials is designed to evaluate the safety and performance of Fantom in more complex cases. Positive results will support indication expansion for Fantom, allowing physicians to confidently expand their use of the product in their patients. Dr. Gregg Stone from the Columbia University Medical Center and the Cardiovascular Research Foundation closed the symposium with an overview of REVA’s future plans for geographic expansion, including information regarding the Company’s proposed trials in the United States and Japan. In addition, Dr. Stone announced REVA’s plans for a thinner version of Fantom (sub-100 micron strut thickness) that is targeted for 2018. This device is being developed to address the issues associated with the use of bioresorbable scaffolds in smaller vessels, and will be a significant addition to the Fantom family of products. The presentation materials delivered at the symposium are available in the Investor Relations section of REVA’s website at www.revamedical.com. REVA is a medical device company located in San Diego, California, USA, that has developed a proprietary bioresorbable scaffold, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s Fantom® scaffold has been designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding the projections and timing surrounding our plans to commence commercial operations and sell products, conduct clinical trials, develop pipeline products, incur losses from operations, list our securities for sale on a U.S. stock exchange, and assess and obtain future financings for operating and capital requirements. Readers should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the “SEC”) on February 28, 2017, and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


News Article | May 18, 2017
Site: globenewswire.com

SAN DIEGO, May 17, 2017 (GLOBE NEWSWIRE) -- Today at the Paris Course on Revascularization (“EuroPCR”), REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) sponsored a symposium entitled, Fantom: performance gains and clinical data for a next generation BRS, which highlighted the recently announced clinical data from the FANTOM II trial. Information regarding the Company’s newly initiated clinical trials and plans for expansion was also presented. Dr. Alexandre Abizaid, Director of Invasive Cardiology at Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, provided a thorough review of the 12-month clinical results from the FANTOM II trial, which were released by the Company yesterday. The results, which included a very low 4.2% rate of Major Adverse Cardiac Events (“MACE”), demonstrate a strong safety profile for Fantom through a sustained timeframe. Dr. Neils Holm from the Skejby-Aarhus University Hospital in Aarhus, Denmark expanded on the nine-month Optical Coherence Tomography (“OCT”) results that were also released by the Company yesterday. The OCT imaging results in a subset of patients treated with Fantom demonstrated vessel patency (maintenance of a wide open artery) and sustained healing with greater than 99% strut coverage at nine months. Dr. Lukasz Koltowski from the Medical University of Warsaw in Poland and Dr. Matthias Lutz from Universitätsklinikum Schleswig-Holstein in Kiel Germany presented a selection of patient case examples from REVA’s recently initiated clinical trials. The FANTOM II Cohort C trial is evaluating the use of Fantom in longer lesions and in multiple vessels. FANTOM AMI is evaluating Fantom in patients that present with an acute myocardial infarction (“AMI”). Each of these trials is designed to evaluate the safety and performance of Fantom in more complex cases. Positive results will support indication expansion for Fantom, allowing physicians to confidently expand their use of the product in their patients. Dr. Gregg Stone from the Columbia University Medical Center and the Cardiovascular Research Foundation closed the symposium with an overview of REVA’s future plans for geographic expansion, including information regarding the Company’s proposed trials in the United States and Japan. In addition, Dr. Stone announced REVA’s plans for a thinner version of Fantom (sub-100 micron strut thickness) that is targeted for 2018. This device is being developed to address the issues associated with the use of bioresorbable scaffolds in smaller vessels, and will be a significant addition to the Fantom family of products. The presentation materials delivered at the symposium are available in the Investor Relations section of REVA’s website at www.revamedical.com. REVA is a medical device company located in San Diego, California, USA, that has developed a proprietary bioresorbable scaffold, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s Fantom® scaffold has been designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding the projections and timing surrounding our plans to commence commercial operations and sell products, conduct clinical trials, develop pipeline products, incur losses from operations, list our securities for sale on a U.S. stock exchange, and assess and obtain future financings for operating and capital requirements. Readers should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the “SEC”) on February 28, 2017, and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


News Article | May 18, 2017
Site: globenewswire.com

SAN DIEGO, May 17, 2017 (GLOBE NEWSWIRE) -- Today at the Paris Course on Revascularization (“EuroPCR”), REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) sponsored a symposium entitled, Fantom: performance gains and clinical data for a next generation BRS, which highlighted the recently announced clinical data from the FANTOM II trial. Information regarding the Company’s newly initiated clinical trials and plans for expansion was also presented. Dr. Alexandre Abizaid, Director of Invasive Cardiology at Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, provided a thorough review of the 12-month clinical results from the FANTOM II trial, which were released by the Company yesterday. The results, which included a very low 4.2% rate of Major Adverse Cardiac Events (“MACE”), demonstrate a strong safety profile for Fantom through a sustained timeframe. Dr. Neils Holm from the Skejby-Aarhus University Hospital in Aarhus, Denmark expanded on the nine-month Optical Coherence Tomography (“OCT”) results that were also released by the Company yesterday. The OCT imaging results in a subset of patients treated with Fantom demonstrated vessel patency (maintenance of a wide open artery) and sustained healing with greater than 99% strut coverage at nine months. Dr. Lukasz Koltowski from the Medical University of Warsaw in Poland and Dr. Matthias Lutz from Universitätsklinikum Schleswig-Holstein in Kiel Germany presented a selection of patient case examples from REVA’s recently initiated clinical trials. The FANTOM II Cohort C trial is evaluating the use of Fantom in longer lesions and in multiple vessels. FANTOM AMI is evaluating Fantom in patients that present with an acute myocardial infarction (“AMI”). Each of these trials is designed to evaluate the safety and performance of Fantom in more complex cases. Positive results will support indication expansion for Fantom, allowing physicians to confidently expand their use of the product in their patients. Dr. Gregg Stone from the Columbia University Medical Center and the Cardiovascular Research Foundation closed the symposium with an overview of REVA’s future plans for geographic expansion, including information regarding the Company’s proposed trials in the United States and Japan. In addition, Dr. Stone announced REVA’s plans for a thinner version of Fantom (sub-100 micron strut thickness) that is targeted for 2018. This device is being developed to address the issues associated with the use of bioresorbable scaffolds in smaller vessels, and will be a significant addition to the Fantom family of products. The presentation materials delivered at the symposium are available in the Investor Relations section of REVA’s website at www.revamedical.com. REVA is a medical device company located in San Diego, California, USA, that has developed a proprietary bioresorbable scaffold, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s Fantom® scaffold has been designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding the projections and timing surrounding our plans to commence commercial operations and sell products, conduct clinical trials, develop pipeline products, incur losses from operations, list our securities for sale on a U.S. stock exchange, and assess and obtain future financings for operating and capital requirements. Readers should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the “SEC”) on February 28, 2017, and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


Patent
Medical University of Warsaw | Date: 2015-07-15

Disclosed herein is a ring prepared from osteoinductive and/or osteogenic material for a use in a dental and orthognathic surgery in case of bone surface deficiency for the introduction of intraosseous dental implants.


Patent
Medical University of Warsaw and Instytut Farmaceutyczny | Date: 2017-02-01

The present invention relates to the antipsoriatic emulsion composition, especially in the form of a cream, comprising an effective therapeutic dose of cefazolin, the ingredients of the oil phase and the ingredients of the water phase, characterized by that(i) the ingredients of the oil phase include:- liquid paraffin or white petrolatum,- polyoxyethylene stearyl ether (21), and- cetostearyl alcohol;(ii) the ingredients of the oil phase include a buffer solution to maintain the pH value of the initial composition from 5 to 9, preferably in the range 6 - 8,(iii) optionally, comprising an additional amphiphilic nonionic emulsifier, and other soluble/water miscible excipients,wherein water content accounts for 50 to 80% by weight of the composition.


Patent
Medical University of Warsaw | Date: 2017-05-24

Disclosed herein is a ring prepared from osteoinductive and/or osteogenic material for a use in a dental and orthognathic surgery in case of bone surface deficiency for the introduction of intraosseous dental implants.


The present invention relates to a prooxidant synergistic combination to treat B-cell malignancies, such as B cell lymphomas, which comprises a thioredoxin reductase inhibitor, selected from a group comprising auranofin and SK053, and L- or D-ascorbate. The combination of the invention exerts synergistic cytotoxic effects towards malignant, but not normal B cells.


Chronic aortic aneurysms are permanent and localized dilations of the aorta that remain asymptomatic for long periods of time but continue to increase in diameter before they eventually rupture. Left untreated, the patients prognosis is dismal, since the internal bleeding of the rupture brings about sudden death. Although successful treatment cures the disease, the risky procedures can result in paraplegia from spinal cord ischaemia or even death, particularly for aneurysms extending from the thoracic to the abdominal aorta and thus involving many segmental arteries to the spinal cord, i.e. thoracoabdominal aortic aneurysms of Crawford type II. Although various strategies have achieved a remarkable decrease in the incidence of paraplegia, it is still no less than 10 to 20%. However, it has been found that the deliberate occlusion of the segmental arteries to the paraspinous collateral network finally supplying the spinal cord does not increase rates of permanent paraplegia. A therapeutic option, minimally invasive segmental artery coil embolization has been devised which proceeds in a staged way to occlude groups of arteries under highly controlled conditions after which time must be allowed for arteriogenesis to build a robust collateral blood supply. PAPA-ARTiS is a phase II trial to demonstrate that a staged treatment approach can reduce paraplegia and mortality dramatically. It can be expected to have both a dramatic impact on the individual patients quality of life if saved from a wheelchair, and also upon financial systems through savings in; 1) lower costs in EU health care; 2) lower pay-outs in disability insurance (est. at 500k in Year 1), and; 3) loss of economic output from unemployment. Approx. 2500 patients a year in Europe undergo these high risk operations with a cumulative paraplegia rate of over 15%; therefore >100M per year in costs can be avoided and significantly more considering the expected elimination of type II endoleaks.


Grant
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: H2020-TWINN-2015 | Award Amount: 1.19M | Year: 2016

In 2013, the Science magazine announced Immunotherapy of cancer as the Breakthrough of the Year. The results of ongoing clinical studies with new cancer immunotherapeutics strongly support this enthusiasm. Following the lead of the top research groups, the Coordinator of the present proposal, Medical University of Warsaw (MUW) displays a predominant ambition of becoming a major player in the thriving area of Immuno-Oncology. MUW is one of the leading centres of competence in the Oncology field in Poland and presents a robust desire for further improvement of its excellence merits. Therefore, the main concept of the STREAM proposal is to bring together the high-level European research organizations with synergistic scientific and innovative expertise in the field of Immuno-Oncology, in order to establish an international, long-term, strategic partnership with MUW. The main model of the STREAM proposal is to foster enhanced scientific dialogue and twinning between MUW and four outstanding research centres via trans-national visits of scientific personnel, joint organization of a summer school and workshops, as well as promoting the active participation of STREAM researchers in the prestigious scientific conferences. Within the duration of the current project we intend to significantly enrich MUWs, regional and national quality profile regarding all of the variables of Composite indicator of Research Excellence in the Immuno-Oncology area. We will also set a new standard for conducting bioresearch and innovative thinking in Poland. We expect that the scale, ambition, and innovative character of the proposed project will bring the MUWs excellence to a new level - internationally recognized and competitive, in order to contribute to the well-being of the society and knowledge-based economy of Poland and EU. Our proposal provides an exceptional occasion to achieve real impact on human health, quality of life and economic status in the new area of enlarged Europe.


Szablewski L.,Medical University of Warsaw
Biochimica et Biophysica Acta - Reviews on Cancer | Year: 2013

It has been known for 80. years that cancer cell growth in an energy-related process supported by an increased glucose metabolism. This phenomenon suggests a need for a corresponding increased uptake of glucose across the plasma membrane through an enhancement in the glucose transporter proteins, SGLT proteins as well as GLUT proteins. The results of many studies have demonstrated that the expression of glucose transporters, especially GLUT1, is increased in a variety of malignancies. GLUT1 overexpression has been found to be associated with tumor progression. It was found that GLUT1 overexpression is associated with poor overall survival in various malignant tumors. © 2012 Elsevier B.V.

Loading Medical University of Warsaw collaborators
Loading Medical University of Warsaw collaborators